News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioForest
Kythera Biopharmaceuticals Announces Two Data Presentations on Its Novel Fat Reduction Drug at ASPS Meeting
October 23, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc.: What: Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat and New Data on Pharmacokinetics, Histology and MOA.
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
GLP-1
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
November 10, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Moderna enjoys stable vaccine sales thanks to global COVID uptake
November 6, 2026
·
4 min read
·
Annalee Armstrong
Podcast
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
October 28, 2026
·
1 min read
·
Jef Akst
Pancreatic cancer
EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
October 27, 2026
·
3 min read
·
Michael Gibney